NEW YORK (TheStreet) — To make the largest deal in its 126-year history an earnings boost, Johnson & Johnson is keeping its acquisition of Synthes as far as from the U.S. taxman as possible.
After receiving regulatory clearance for its $19.7 billion acquisition of Swiss medical device maker Synthes, Johnson & Johnson says the mega-deal will add to earnings per share after previously forecasting dilution: All with the help of bankers JPMorgan Chase and Goldman Sachs. …
Click to view a price quote on JNJ.Click to research the Drugs industry.
Penny Stock Picks
Forty Six & 2